

PRESCRIBING INCENTIVE SCHEME 2008-2009

Indicator	Measure	Total Points Available	Min Threshold	Max Threshold
1. Financial Target	Practice must achieve one of the following: a) Stay within prescribing budget (after allowance for high cost specialist drugs) or b) Demonstrate a cost per ASTRO-PU equal to or less than the PCT average or c) Demonstrate a growth in prescribing costs equal to or below 3%	4	N/A	N/A
2. Locality Meetings	The named prescribing lead will: a) Attend up to 3 Locality Prescribing Meetings by 31 st March 2009 and b) Must support implementation of the Prescribing Incentive Scheme and the QOF action points from practice visits	4	2 meetings (2 points)	3 meetings (3 points)
3. Repeat Prescribing	The practice will be required to: a) Release the Practice Manager or repeat prescribing administrative staff to attend a PCT organised repeat prescribing meeting before 31 st March 2009 (date of meeting to be advised) b) Produce a repeat prescribing protocol based on good practice (template from PCT Prescribing Team to follow) c) Audit the percentage of repeat prescription requests processed within 48 hours over a period of one week before 31 st March 2009 (template from PCT Prescribing Team to follow)	6	N/A	4 points
4. Percentage Formulary Antibiotics	Percentage of oral antibiotics prescribed from the recommended list of first line antibiotics ie: Amoxicillin Penicillin V Flucloxacillin Erythromycin Trimethoprim Metronidazole Oxytetracycline Tetracycline	2	75% (1 point)	80% (2 points)

5. Rate of Antibiotic Prescribing	Rate of antibiotic prescribing	2	≤800 Items/1000 STAR-PU in 12 months (1 point)	≤700 items/1000 STAR-PU in 12 months (2 point)
6. Cephalosporins	Rate of cephalosporin prescribing	2	≤40 items/1000 STAR-PU in 12 months (1 point)	≤30 items/1000 STAR-PU in 12 months (2 point)
7. Quinolones	Rate of quinolone prescribing (ie: ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin and nalidixic acid)	2	≤34 items/1000 STAR-PU in 12 months (1 point)	≤29 items/1000 STAR-PU in 12 months (2 point)
8. Recommended Generic / Formulations	Percentage of specified generic and specific-formulation products prescribed Recommended generic products / formulations include: Lansoprazole capsules Omeprazole capsules Alendronic acid 70mg tablets Ramipril capsules Tamsulosin MR 400mcg capsules Amlodipine Lisinopril Citalopram Simvastatin Pravastatin Fluoxetine	3	90% (1 point)	95% (3 points)
9. Proton Pump Inhibitors	Percentage of proton pump inhibitors prescribed as either lansoprazole or omeprazole	3	90% (1 point)	95% (3 points)
10. Statin Audit	Practices must submit an audit showing percentage of patients prescribed statins for primary and secondary prevention (audit template from PCT Prescribing Team to follow) The data breakdown should include the percentages for diabetic and non-diabetic patients The audit must be submitted to the PCT Prescribing Team by 31 st March 2009	3	N/A	N/A

11. Dementia / Antipsychotic Audit*	<p>The practice will be required to:</p> <p>a) Audit the repeat prescribing of antipsychotic medications for patients over the age of 65, diagnosed with dementia (in the absence of a definitive SMI diagnosis) who are a resident in a care home</p> <p>and</p> <p>b) Review the prescribing of risperidone and olanzapine in care home patients aged over 65, suffering from dementia, who have received one of these drugs for more than 12 weeks. (audit template from PCT Prescribing Team to follow)</p> <p><i>NB Atypical antipsychotic drugs are associated with a 3 fold increase in the risk of stroke in elderly patients with dementia. Therapy should not generally be considered beyond 12 weeks.</i></p>	6	N/A	1 point
12. Adverse Drug Reactions	<p>a) Practice to submit a quarterly report to the PCT on the number of yellow cards for black triangle drugs reported to MHRA by your practice.</p> <p>and</p> <p>b) Practice to submit a quarterly report to the PCT on number of yellow card reports of known significant side effects in non black triangle drugs reported to MHRA by your practice.</p> <p>and</p> <p>c) Practice to submit a quarterly report to the PCT on the number of new drug intolerances recorded in the practice system between 1st April 2008 and 31st March 2009</p> <p>(audit templates from PCT Prescribing Team to follow)</p>	3	N/A	1 point
			N/A	1 point
			N/A	1 point

* Practices that do not have any care home patients should contact the PCT Prescribing Team and agree a different audit that they can undertake to meet this target.